Introduction
============

Esophageal adenocarcinoma (EAC), including cancers of the gastro-esophageal junction, represent a substantial health concern in Western countries due to its increasing incidence and poor prognosis. To date, there are no widely accepted animal models for EAC and a limited number of cell lines are all that are available for *in vitro* functional studies. Recent genome-wide sequencing projects have shown that EAC is one of the most highly mutated solid cancers with a high degree of heterogeneity ( [@ref-6]; [@ref-15]). In addition to point mutations there are also widespread copy number alterations with evidence of catastrophic events such as chromothripsis and bridge fusion breakages in about one-third of cases ( [@ref-10]). An accurate annotation of the mutational landscape of available EAC cell lines is therefore crucial for optimal experimental design, interpretation of genotype-phenotype data and to analyse drug sensitivities. We selected eight EAC cell lines---ESO26, ESO51, FLO-1, JH-EsoAd1, OACM5.1 C, OACP4 C, OE33, SK-GT-4---the identities of which have been verified by short tandem repeat (STR) analysis, p53 mutation and xenograft histology against the original tumors ( [@ref-4]), and one esophageal high grade dysplasia (CP-D) cell line. We performed high-coverage paired-end whole genome sequencing and aligned the sequence data to the human reference genome in order to detect single nucleotide variants, indels and copy number alterations.

Materials and methods
=====================

Ethics
------

Cell lines were obtained through commercially available repositories except JH-EsoAd1, which was a kind gift from Hector Alvarez ( [Table 1](#T1){ref-type="table"}).

###### Characteristics and clinico-pathological features of the EAC cell lines analysed.

Verified origin identifies cell lines whose pathological origin from EAC has been verified in [@ref-4].

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cell line       Alternative\   Age     Sex   Ethnicity   Histology                Date\     Stage        Ploidy                 Commercial\          Verified\   Ref
                  Names                                                             Derived                                       Availability         origin      
  --------------- -------------- ------- ----- ----------- ------------------------ --------- ------------ ---------------------- -------------------- ----------- ------------
  **CP-D**        CP-18821       Adult   M                 hTERT immortalized\      1995      HGD          hypoyhetraploid        ATCC                             [@ref-11]\
                                                           oesophageal HGD                                                                                         [@ref-10]

  **ESO26**                      56      M     Caucasian   GOJ\                     2000      Stage IV     hypodiploid (1.8)      Public Health\       YES         [@ref-4]
                                                           adenocarcinoma                                                         England --Culture\               
                                                                                                                                  Collection                       

  **ESO51**                      74      M     Caucasian   Distal Oesophageal\      2000      Stage IV     hypotriploid (2.75)    Public Health\       YES         [@ref-4]
                                                           Adenocarcinoma                                                         England --Culture\               
                                                                                                                                  Collection                       

  **FLO-1**                      68      M     Caucasian   Distal Oesophageal\      1991                   hypodiploid (1.9)      Public Health\       YES         [@ref-8]
                                                           Adenocarcinoma                                                         England --Culture\               
                                                                                                                                  Collection                       

  **JH-EsoAd1**   JHAD1          66      M     Caucasian   Moderately to\           1997      Stage IIA\   triploid               No, due to be\       YES         [@ref-2]
                                                           poorly differentiated\             (T3 N0 M0)                          deposited in ATCC                
                                                           Oesophageal\                                                                                            
                                                           Adenocarcinoma                                                                                          

  **OACM5.1C**                   47      F     Caucasian   Lymph node\              2001      Stage IV     hypodiploid            Public Health\       YES         [@ref-5]
                                                           metastases of\                                                         England --Culture\               
                                                           Distal Oesophageal\                                                    Collection                       
                                                           Adenocarcinoma                                                                                          

  **OACP4 C**                    55      M     Caucasian   Gastric cardia\          2001      Stage IV     Aneuploidy (53--57\    Public Health\       YES         [@ref-5]
                                                           adenocarcinoma                                  chromosomes)           England --Culture\               
                                                                                                                                  Collection                       

  **OE33**        JROECL33       73      F                 Distal Oesophageal\      1993      Stage IIA    hypotetraploid (3.5)   Public Health\       YES         [@ref-13]
                                                           Adenocarcinoma                                                         England --Culture\               
                                                                                                                                  Collection                       

  **SK-GT-4**                    83      M                 Distal Oesophageal\      1989      Stage IIB    Aneuoplid (mode 59\    Public Health\       YES         [@ref-1]
                                                           Adenocarcinoma                                  chromosomes, SK        England --Culture\               
                                                                                                                                  Collection                       
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cell lines
----------

All cell lines were from a certified source ( [Table 1](#T1){ref-type="table"}) and verified in house for \>90% match with publicly reported STR profiles. Cell lines were mycoplasma tested and grown in standard conditions reported in cell repositories indicated in [Table 1](#T1){ref-type="table"}. Matched germline DNA was not available.

Library preparation, sequencing and QC
--------------------------------------

Genomic DNA was prepared from cultured cells with AllPrepDNA/RNA Mini Kit (Qiagen) according to manufacturer's instructions. A single library was created for each sample, and 90-bp paired-end sequencing was performed at Beijing Genomic Institute (BGI, Guangdong, China) according to Illumina (Ca, USA) instructions to a typical depth of 30×, with 94% of the known genome being sequenced to at least 10× coverage and achieving a Phred quality of 30 for at least 80% of mapping bases. FastQC 0.11.2 ( <http://www.bioinformatics.babraham.ac.uk/projects/fastqc>) was used to assess the quality of the sequence data. Additional alignment, duplication and insert size metrics quality metrics are reported in [Supplementary material 7](#SM7){ref-type="other"}. Sequence reads were mapped to the human reference genome (Ensembl GRCh37, release 84) using BWA 0.5.9 (Li, 2009), sorted into genome coordinate order and duplicates marked using Picard 1.105 (FixMateInformation and MarkDuplicates tools respectively, <http://broadinstitute.github.io/picard>). Original BAM files are available in the European Bioinformatics Institute (EBI) repository (project: PRJEB14018; sample accessions: ERS1158075-ERS1158083).

Mutation calling
----------------

GATK v3.2.2 (Broad Institute, MA, USA) was used to call and filter single nucleotide and indel variants compared to the reference genome. In brief, the steps run were as follows: 1) local realignment of reads to correct misalignments around indels using GATK RealignerTargetCreator and IndelRealigner tools; 2) recalibration of base quality scores using GATK BaseRecalibrator tool; 3) SNV and indel calling using GATK HaplotypeCaller which determines haplotype by re-assembly within regions determined to be active, i.e. where there is evidence for a variation, and uses a Bayesian approach to assign genotypes. Hard filters were applied to the resulting call set using recommendations available from the GATK documentation ( <https://www.broadinstitute.org/gatk>) to generate a high-confidence set of SNV and indel calls. These were analyzed with Ensembl Variant Effect Predictor (release 75, <http://www.ensembl.org/info/docs/tools/vep/index.html>) to annotate with genomic features and consequences of protein coding regions ( [Supplementary material 4](#SM4){ref-type="other"}). For the purposes of the analysis, all variants with global minor allele frequency (GMAF) \>0.0014 described in the 1000 Genomes project were separated out as likely germline polymorphisms ( [@ref-14]) according to the criteria adopted in the Cosmic Cell Lines Project (Wellcome Trust Sanger Institute, Cambridge). Further, we removed all SNPs that have a minor allele frequency in the DBSNP (Ensembl v.58) and variants with a frequency ≥0.00025 in the ESP6500 (NHLBI GO Exome Sequencing Project, released June 20th 2012). A full list of the filtered variants is available in [Supplementary material 4](#SM4){ref-type="other"} and [Supplementary material 6](#SM6){ref-type="other"}.

Copy number assessment
----------------------

Copy number (CN) analysis was carried out using Control-FREEC ( [@ref-3]). Control-FREEC computes and segments CN profiles and is capable of characterizing over-diploid genomes, taking into consideration the CG-content and mapability profiles to normalize read count in the absence of a control sample. Ploidy in each cell line was assessed interactively with the Crambled app v.2.0 according to the methods described by [@ref-9].

Dataset validation
==================

Whole genome sequencing
-----------------------

We identified a median of 1.3×10 ^5^ variants across all 9 cell lines (range 105,487--151,879; [Figure 1a](#f1){ref-type="fig"}, [Table 2](#T2){ref-type="table"}, [Supplementary material 3](#SM3){ref-type="other"}, [Supplementary material 4](#SM4){ref-type="other"}). We found that 1,5% of the variants were in coding regions; additionally, 4% fell in surrounding gene regions (i.e. regulatory as defined in [@ref-16], upstream and downstream regions), 41% in introns and 23% in intergenic regions. Among the variants in the coding sequence, the majority, 57.4%, were in the UTR regions, followed by exonic missense and synonymous variants (21% and 11% respectively ( [Figure 1](#f1){ref-type="fig"}, [Table 2](#T2){ref-type="table"}, [Supplementary material 3](#SM3){ref-type="other"}, [Supplementary material 4](#SM4){ref-type="other"}). The number of variations identified in the high-grade dysplasia CP-D line was not significantly lower to the median of other EAC cell lines, consistent with the finding that such pre-malignant lesions have already accumulated many SNVs ( [@ref-15]). OACP4C and ESO26 showed the smallest and largest number of variants, respectively. ( [Figure 1](#f1){ref-type="fig"}, [Table 2](#T2){ref-type="table"}).

![Distribution of detected variants and coding sequence consequences (mean percentage value).\
**A**) Bar chart showing the distribution of called variants across various regions of the genome as indicated; **B**) Details of the coding sequence variants identified by the Variant Effect Predictor (Ensembl) expressed as a mean percentage value of all cell lines (values were not statistically different among samples).](f1000research-5-7571-g0000){#f1}

###### Detailed distribution of identified variants for each cell lines.

Absolute number, median, median absolute deviation and range interval are listed for each category of mutation according to Variant Effect Predictor classification (Ensembl).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                   CP-D         ESO26        ESO51        FLO-1        JH-EsoAD1    OACM5.1      OACP4C       OE33         SK-\         Median       Median\     Min          Max
                                                                                                                                                           GT-4                      Absolute\                
                                                                                                                                                                                     Deviation                
  --------------- -------------- ----------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ ----------- ------------ ------------
  **Coding**\     UTR            5 prime UTR       229          301          262          191          206          264          229          216          305          229          33          **191**      **305**
  **variants**\                                                                                                                                                                                               
  **(type)**                                                                                                                                                                                                  

                  3 prime UTR    979               1097         1002         926          929          1026         848          986          1113         986          57           **848**     **1113**     

                  Start/Stop     initiator codon   1            3            2            2            3            2            1            0            1            2            1           **0**        **3**

                                 stop lost         2            2            4            2            2            2            3            3            2            2            0           **2**        **4**

                                 stop retained     2            1            4            2            2            1            2            2            2            2            0           **1**        **4**

                                 stop gained       10           14           17           16           14           17           9            14           24           14           3           **9**        **24**

                  Missense       missense          385          496          497          436          435          481          431          446          454          446          15          **385**      **497**

                  Splice Sites   splice\           4            11           7            8            11           11           9            7            7            8            1           **4**        **11**
                                 acceptor                                                                                                                                                                     

                                 splice donor      5            7            6            10           6            9            6            5            18           6            1           **5**        **18**

                                 splice region     105          113          107          92           96           95           83           103          102          102          6           **83**       **113**

                  Frameshift\    frameshift        42           52           41           45           34           34           49           46           54           45           4           **34**       **54**
                  INDEL                                                                                                                                                                                       

                  In Frame\      inframe\          11           10           15           18           15           14           10           15           20           15           3           **10**       **20**
                  INDEL          deletion                                                                                                                                                                     

                                 inframe\          10           17           19           8            14           10           11           8            16           11           3           **8**        **19**
                                 insertion                                                                                                                                                                    

                  Synonymous                       199          278          284          259          221          283          202          208          242          242          36          **199**      **284**

                  Other                            1            1            1            0            1            1            1            1            1            1            0           **0**        **1**

  **Non**\        Gene\          downstream        19197        20411        18927        18009        17711        19363        16202        18463        20318        18927        918         **16202**    **20411**
  **coding**\     boundaries                                                                                                                                                                                  
  **variants**\                                                                                                                                                                                               
  **(regions)**                                                                                                                                                                                               

                  upstream       19197             20761        19332        18122        18196        20182        16825        18944        21239        19197        1001         **16825**   **21239**    

                  Intergenic                       29694        38091        34040        31999        27269        31875        21550        32985        33380        31999        2041        **21550**    **38091**

                  Introns                          55372        61682        56671        54869        51163        56193        43210        55945        61374        55945        1076        **43210**    **61682**

                  Non-coding\    Mature\           8            13           6            6            5            10           5            8            4            6            2           **4**        **13**
                  transcripts    miRNA                                                                                                                                                                        

                                 non-coding\       1            2            1            1            1            1            0            0            1            1            0           **0**        **2**
                                 transcript                                                                                                                                                                   

                                 non coding\       2149         2200         2116         1868         1920         2113         1811         2095         2310         2113         87          **1811**     **2310**
                                 transcript\                                                                                                                                                                  
                                 exon                                                                                                                                                                         

                  Regulatory\    TF binding\       404          453          469          431          413          500          408          440          486          440          29          **404**      **500**
                  regions        site                                                                                                                                                                         

                                 regulatory\       4667         5863         5301         4686         4512         5011         3582         4778         6158         4778         266         **3582**     **6158**
                                 region                                                                                                                                                                       

                                                   **132674**   **151879**   **139131**   **132006**   **123179**   **137498**   **105487**   **135718**   **147631**   **135718**   **3712**    **105487**   **151879**
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A limitation of this study is represented by the lack of an available normal counterpart. In order to overcome this problem, in addition to the GATK calling pipeline we have applied a series of filters according to the criteria reported in methods and derived the 1000 Genomes Project ( [@ref-14]), DBSNP (Ensembl v.58) and ESP6500 (released June 20 ^th^ 2012). This approach reduced the number of variants by an order of magnitude from the original GATK pipeline (from a median of 4.1×10 ^6^ to 1.3×10 ^5^). Yet, the abundance of called variants compared to a range of 4,8×10 ^3^-6×10 ^4^ reported in human EAC ( [@ref-15]), may indicate that a proportion of the variants called in our final annotation are of germline origin. Also, additional mutations may have accumulated *in vitro*. A comprehensive annotation of the coding sequence variants identified is reported in [Supplementary material 3](#SM3){ref-type="other"} and [Supplementary material 4](#SM4){ref-type="other"}.

Analysis of putative EAC driver genes
-------------------------------------

In order to investigate how closely cell lines reflect the spectrum of mutations observed in human specimens we analysed the mutational landscape of known cancer and putative EAC driver genes and compared to the previously reported mutation rate ( [@ref-6]; [@ref-15]; [Figure 2b & 2c](#f2){ref-type="fig"}). 69% of EACs have TP53 mutations ( [@ref-15]), while all cell lines carried at least one deleterious TP53 mutation. A SMAD4 mutation was present in 2 of 9 cell lines, ESO26 and JH-EsoAd, consistent with the 13% observed in EAC ( [@ref-15]). We were not able to identify mutations in ARID1A (affected by UTR variants in 1 of 9 cell lines) that is reportedly mutated in about 10% of cases of EAC specimens. Only some of the missense variants in the genes shown in [Figure 2b](#f2){ref-type="fig"} resulted in known pathogenic mutations (i.e. TP53, PIK3CA, and TLR4). Other genes harboured benign or likely benign variants and/or variants with uncertain functional significance.

![Analysis SNV and CNA of putative EAC genes identified in [@ref-6] and [@ref-15].\
**A**) Log ratio of copy number status of the selected genes computed with Control-Freec (green indicates CN gain and red CN loss). Genome wide CN for each line is available in [Supplementary material 1](#SM1){ref-type="other"} and [Supplementary material 3](#SM3){ref-type="other"}. **B**) SNVs identified by our pipelines and annotated by Variant Effect Predictor analysis (Ensembl). When more than one variant was present in a single gene, the most deleterious was annotated according to the color-coded legend reported at the bottom of the figure. A complete annotation of identified SNV are available in the [Supplementary material 2](#SM2){ref-type="other"}. **C**) Blue and red bars indicate the mutation rate of EAC genes reported in [@ref-6]; and [@ref-15], respectively.](f1000research-5-7571-g0001){#f2}

We expanded our analysis to other cancer genes of potential relevance to OAC. We identified a pathogenic KRAS mutation in SKGT4, and a missense mutation of uncertain significance in MET (OE33), EGFR (CP-D, ESO26, IH-EsoAd1). Among DNA repair genes all cell lines carry benign missense variants of ATM and missense variants of uncertain significance in BRCA2. MSH2 is affected by a missense variant in SKGT4, splice site variants in CP-D, JH-EsoAd1, and UTR variants in ESO51 and OACP4 C ( [Supplementary material 3](#SM3){ref-type="other"}, [Supplementary material 4](#SM4){ref-type="other"}, [Supplementary material 6](#SM6){ref-type="other"}). Copy number analysis ( [Supplementary material 1](#SM1){ref-type="other"}, [Supplementary material 2](#SM2){ref-type="other"}) identified recurrent amplifications in ERBB2, MYC, MET and SEMA5A, and deletions in SMAD4, CDKN2A, CCDC102B and SMARCA4.

This sequencing data will enable the research community to undertake and interpret further analyses (reviewed in [Supplementary material 5](#SM5){ref-type="other"}) and to inform the use of these cell lines as a model of EAC. Our data highlight the need to develop additional *in vitro* models that have a germline reference genome to identify clearly the somatic changes ( [@ref-7]). A larger number of cell lines might also more closely recapitulate the range of mutations observed in human disease.

Data availability
=================

The data referenced by this article are under copyright with the following copyright statement: Copyright: © 2016 Contino G et al.

BAM files are available at the European Nucleotide Archive (ENA, EMBL-EBI, [www.ebi.ac.uk/ena](http://www.ebi.ac.uk/ena), Study PRJEB14018). Accession numbers: CP-D ERS1158083; SK-GT-4 ERS1158082; OE33 ERS1158081; OACP4 C ERS1158080; OACM5.1 ERS1158079; JH-EsoAd1 ERS1158078; FLO-1 ERS1158077; ES051 ERS1158076; ES026 ERS1158075.

Supplementary material
======================

**Supplementary material 1.** **A**) Copy Number Alteration of EAC cell lines according to ploidy shown by FREEC plots (loss, normal, and gain are indicated in blue, green and red, respectively). Genes annotated in red are the genes of the Cancer Genes Cosmic Census that fall in the amplified regions defined as copy number ≥5 for diploid and ≥7 for triploid and tetraploid cell lines. Genes annotated in blue are genes of the Cancer Genes Cosmic Census that fall in deleted regions with CN ≤1. **B**) Tables reporting all the genes of the Cancer Genes Cosmic Census that falls in deleted or amplified regions according to FREEC. Cell lines are shown in the following order 1) CP-D, 2) ESO26, 3) ESO51, 4) FLO-1, 5) JH-EsoAd1, 6) OACM5.1 C, 7) OACP4 C, 8) OE33, 9) SK-GT-4. Click here for additional data file..

**Supplementary material 2.** FREEC output of CNV by chromosome of the analysed cell lines. CNV of each cell line is indicated by chromosome consistently to known ploidy and *in silico* verification with the *Crambled App* (Lynch *et al.*, 2015). Click here for additional data file..

**Supplementary material 3.** Effect Predictor Analysis annotated VCF files of GAKT called variants for CP-D, ESO26, ESO51, FLO-1, JH-EsoAd1, OACM5.1 C, OACP4 C, OE33, SK-GT-4 are available for download at the EMBL-EBI European Variation Archive (EVA, <http://www.ebi.ac.uk/eva/>) under the study PRJEB14018).

**Supplementary material 4.** Filtered variants: 1) CP-D, 2) ESO26, 3) ESO51, 4) FLO-1, 5) JH-EsoAd1, 6) OACM5.1 C, 7) OACP4 C, 8) OE33, 9) SK-GT-4. Click here for additional data file..

**Supplementary material 5.**. Publicly Available datasets for analysed cell lines. For each cell line, currently available datasets from COSMIC, the Broad-Novartis Cancer Cell Line Encyclopaedia, and GEO (Gene Expression Omnibus) are listed. Click here for additional data file.

**Supplementary material 6.**. Gitools readable file containing mutation calls for all genes. When more than one variant was present in a single gene, the most deleterious was annotated according to the color-coded legend reported at the bottom of the figure. Gitools is freely available for download at [www.gitools.org](http://www.gitools.org) ( [@ref-12]). Click here for additional data file..

**Supplementary material 7.** Alignment, duplication and insert size metrics for each cell line. Click here for additional data file..
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In this study Contino present their WGS analysis of 9 (verified) oesophageal adenocarcinoma cell lines. This is an adequate platform to present these data and the fact that the authors make all raw BAM files easily accessible to the community means that this study is particularly valuable to colleagues looking to contrast cell lines with particular genomic aberrations or different neo-antigenic burdens. Such studies always come with the known caveats of *in vitro*selection and the authors rightfully acknowledge this. As expected, the study in large part confirms earlier large scale sequencing studies of primary material. The lack of a patient-specific reference control means that the impact of more subtle genomic abnormalities in for example regulatory regions remain difficult to study. Nonetheless this work represents a valuable addition to previously published datasets and the authors are to be commended for publishing this analysis. The paper is terse and I enjoyed reading this study.
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The authors have performed whole genome sequencing of eight esophageal adenocarcinoma cell lines and one esophageal high grade dysplastia cell line to an average depth of 30x.  The authors have made the BAM and VCF files available through the EBI repository and this will be an excellent resource for researchers working on this cancer.  We feel the methods used are appropriate and most of the analyses described are informative.  We do however have a few suggestions for the authors to address, these are listed below:

Dataset validation WGS section: Clarify the % of variants that fall in each sequence context, coding, intronic, regulatory, intergenic.  We assume this should sum to 100%.In the next sentence there is a "("instead of a " ," "in front of the 21% and 11% respectively"Table 1: ploidy state of CP-D, should this be hypotetrapoid?Paragraph 2 of this section: Change 4,8x10 ^3^ to 4.8x10 ^3^MuTect was used as variant caller in the Dulak paper and SomaticSniper was used in the Weaver paper.  The authors should explain that they can't use a somatic variant caller as these require a \"normal\" sample and also that application of a different caller for this cell line project may also make comparisons with the Dulak and Weaver papers less powerful.

Analysis of putative EAC driver genes: There isn't an ARID1A UTR variant shown for any of the cell lines in Figure 2b yet the authors mention 1 of the 9 cell lines has such a variant in the text. On a related note we think the authors should consider the relevance of including UTR and synonymous changes in figure2b.  We don't think that these are considered in the Dulak and Weaver papers and are, as far as we understand, unlikely to be functional.Second sentence of the second paragraph needs clarifying.  Presumably missense mutations were found in MET and EGFR? IH-EsoAd1 should be JH-EsoAd1 in the same sentence.Authors should make more of the fact that they have sequenced whole genomes whereas the COSMIC cell line project has only sequenced cell line exomes.  The authors could perhaps highlight the useful extra data that is available from this sequencing effort, such as identification of mutations in putative regulatory regions and germline variants.  Both classes of variants will be of interest to researchers working on understanding the genetics of oesophageal adenocarcinoma and wishing to identify appropriate cell models to work with.
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The authors have examined the DNA sequences of 8 oesophageal adenocarcinoma cells lines and one high-grade dysplasia cell line, The authors should be congratulated for tackling this important unmet need in oesophageal cancer research and publishing these important findings in such an accessible manner. As the authors state, oesophageal adenocarcinoma seems to be one of the cancers carrying the most mutations, and although several cell lines, including those utilized in this study are commonly used for laboratory studies, there has never been a systemic study of the genetic abnormalities in these cells lines. The data in this study does fill that important gap, allowing comparisons between them and the cancer *in vivo*.

The methods are appropriate for the study and well-described and the abstract accurately represents the contents of the study. The results are appropriately and clearly presented. The conclusions appear to be sound based on the data presented and most importantly the paper provides the data to enable other researchers to build on these data and hopefully further refine laboratory models for oesophageal adenocarcinoma.
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